Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.45 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931265 | 0.85 | MAPK14 (0.54) | MAPK14MAPK11ALOX5CSNK1DCSNK1E | |
| SCHEMBL7074037 | 0.82 | MAPK14 (0.56) | MAPK14MAPK11ALOX5CSNK1DCSNK1E | |
| SCHEMBL5789108 | 0.82 | MAPK14 (0.57) | MAPK14MAPK11ALOX5CSNK1DCSNK1E | |
| SCHEMBL6935697 | 0.81 | MAPK14 (0.51) | MAPK14MAPK11ALOX5CSNK1DCSNK1E | |
| SCHEMBL5792669 | 0.80 | MAPK14 (0.68) | MAPK14MAPK11ALDH1A1MAPK13MAPK12 | |
| SCHEMBL6935696 | 0.79 | MAPK14 (0.51) | MAPK14MAPK11ALOX5CSNK1DCSNK1E | |
| SCHEMBL6933880 | 0.76 | MAPK14 (0.51) | MAPK14MAPK11ALOX5CSNK1DALDH1A1 | |
| SCHEMBL6929508 | 0.74 | CYP3A4 (0.55) | MAPK14MAPK11CSNK1DCSNK1A1MAPK13 | |
| SCHEMBL6934712 | 0.74 | MAPK14 (0.47) | MAPK14MAPK11ALOX5CSNK1DCSNK1E | |
| SCHEMBL6932796 | 0.73 | MAPK14 (0.46) | MAPK14MAPK11ALOX5CSNK1DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1328277-C | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| CN-1246858-A | Substituted pyrimidine compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| CN-1246857-A | Substituted pyrimidinone and pyridinone compounds and their use | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | MAPK14 2062/4885MAPK11 1618/4885ALOX5 204/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | MAPK14 1169/4885MAPK11 1375/4885ALOX5 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.